MDT stock forecast, quote, news & analysis

Key Takeaways

• Medtronic (MDT) climbed from a closing price of $86.29 on September 30, 2026 to $96.54 on October 30, 2026, a gain of approximately +11.9% over 30 days.
• The move was driven primarily by the completed separation of its diabetes business, MiniMed Group, whose oversubscribed exchange offer retired roughly 55 million Medtronic shares.
• Strong fiscal 2027 first-quarter results, new reimbursement codes, European regulatory approvals, and constructive analyst actions reinforced the rally.
• Over the trailing quarter, the stock advanced roughly 12% to 13%, building on a broader recovery from its mid-2026 lows.
• Medtronic raised its quarterly dividend again and now stands one increase away from Dividend King status after 49 consecutive years of dividend growth.
• For additional context on valuation, upcoming results, and long-term projections, explore dedicated Price Targets, Earnings, and Forecast pages.
• To see how automated strategies are positioning around this ticker, explore Trending AI Robots.

Medtronic (MDT) Company Overview and Market Position

Medtronic plc is one of the world's largest medical technology companies, operating across cardiovascular, neuroscience, medical surgical, and diabetes-related portfolios. Its products include cardiac rhythm management devices, cardiac ablation systems, surgical technologies, spinal and cranial implants, and robotic-assisted surgery platforms such as Hugo and Stealth AXiS. After completing the spin-off of its diabetes segment, MiniMed Group, Medtronic now concentrates on its cardiovascular, neuroscience, and surgical franchises. Investors follow the stock for its diversified revenue base, recurring procedure-driven demand, defensive profile, and a long track record of shareholder returns, including a dividend it has increased for nearly five decades.

Medtronic (MDT) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, MDT rose from a closing price of $86.29 on September 30, 2026 to $96.54 on October 30, 2026, a gain of approximately +11.9%. The advance was punctuated by a pronounced volume spike in mid-October as the MiniMed exchange offer settled, followed by steady gains through the end of the month, with the stock closing at $96.54 after reaching an intraday high above $98.

The quarterly trend tells a similar but slightly broader story. From a closing price near $85.71 at the end of July 2026, the shares gained roughly 12.6% through the end of October. The stock had traded as low as roughly $72.50 in early June 2026 and has since staged a multi-month recovery, with the late-October move carrying the price back toward the upper end of its recent trading range.

What Drove MDT Stock Price in the Last 30 Days

The central catalyst was the completion of Medtronic's separation of MiniMed Group. The split-off and exchange offer was heavily oversubscribed, and as part of the final settlement on October 15, 2026, Medtronic received approximately 55 million of its own shares, reducing its share count and providing an earnings-per-share benefit. The event also confirmed Medtronic's strategic focus on its higher-margin cardiovascular, neuroscience, and surgical businesses.

Supporting the move were several additional developments. On October 1, Medtronic announced the approval of new CPT codes for its Altaviva and Symplicity Spyral devices, effective January 2028. The company also secured CE Mark approval for its Vitalis pacemaker portfolio in Europe and presented positive real-world registry data for its Sphere-9 catheter and PulseSelect system at the APHRS 2026 conference. The Stealth AXiS surgical system and Corsano wearable were additionally recognized on TIME's 2026 Best Inventions list.

Analyst activity remained broadly constructive. RBC Capital reiterated a Buy rating with a $118 price target in early October, and BTIG maintained a Buy rating with a $99 target, while Piper Sandler and J.P. Morgan reiterated Hold ratings. The combination of corporate action, regulatory progress, and product momentum outweighed a more cautious tone from some analysts.

What Drove MDT Stock Performance Over the Last Quarter

The quarterly gain reflects a wider recovery narrative. Medtronic's fiscal 2027 first quarter, ended July 31, 2026, showed revenue of approximately $9.76 billion, up 13.7% year over year, with adjusted earnings per share of $1.45 that exceeded consensus estimates near $1.39. Strength was led by the cardiovascular segment, which grew about 19%, while cardiac ablation solutions revenue rose sharply as the Affera and Sphere-9 platforms gained traction.

Beyond the quarterly results, investors responded to the long-planned MiniMed separation, which management expects to expand operating margins by roughly 100 basis points. Medtronic also raised its quarterly dividend by 1.4% to $0.72 per share, extending a streak of 49 consecutive years of increases and positioning the company for Dividend King status. These factors, combined with a defensive healthcare tilt in the broader market, supported the multi-month recovery from the stock's mid-2026 low.

Trending AI Robots

Tickeron operates hundreds of AI-driven trading bots that trade thousands of tickers, but only the top-performing and most relevant strategies appear in the curated Trending AI Robots section. These bots vary by strategy, holding timeframe, and performance metrics, giving traders a way to compare automated approaches across different market conditions. The section is designed to surface the strategies currently demonstrating the strongest signals, helping users identify tools that align with their own objectives. Investors tracking names like Medtronic can use the page to observe how momentum and technical signals are being interpreted in real time.

MDT Stock Forecast Drivers: What Investors Should Watch Next

The next earnings report, expected in mid-November 2026, is the most immediate focus, with consensus estimates around $1.34 in earnings per share and roughly $9.47 billion in revenue. Investors will watch whether organic revenue growth holds near the double-digit pace seen in the most recent quarter, how the MiniMed separation affects reported margins, and whether management updates full-year guidance. Additional factors include the pace of adoption for Affera, Sphere-9, Altaviva, and Symplicity Spyral, the rollout of the Hugo and Stealth AXiS surgical platforms, competitive dynamics from peers such as Johnson & Johnson, Abbott Laboratories, and Stryker, and broader macroeconomic and healthcare-policy developments. These items are presented for informational purposes only and are not investment recommendations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations